Skip to main content
. 2023 Oct 6;62(12):1713–1724. doi: 10.1007/s40262-023-01306-7

Table 2.

Summary of PK parameters

PK parametera Participants with renal and hepatic impairment (N = 11) Healthy controls (N = 11)
AUC (h⋅ng/mL) 4736 (23.12) 2249 (19.51)
AUClast (h⋅ng/mL) 4720 (23.16) 2237 (19.53)
AUC0–24 (h⋅ng/mL) 3483 (23.07) 2032 (19.09)
Cmax (ng/mL) 279.1 (29.07) 261.3 (33.52)
C24 (ng/mL) 71.11 (35.09) 17.60 (46.00)
tmax (h) 3.00 (1.50–10.00) 1.50 (0.50–4.00)
t½λz (h) 14.66 (20.94) 9.818 (40.94)
λz (/h) 0.04729 (20.94) 0.07060 (40.94)
CL/F (L/h) 1.056 (23.12) 2.224 (19.51)
CLNR/F (L/h) 0.8487 (42.97) 0.9716 (14.72)
Vz/F (L) 22.32 (36.53) 31.50 (37.10)
CLR (L/h) 0.1080 (154.0) 1.224 (32.34)
Ae (0–72) (mg) 0.5007 (147.5) 2.740 (15.45)
Fe (0–72) (%) 10.01 (147.5) 54.80 (15.45)

λz terminal elimination rate constant, Ae amount of unchanged drug excreted into urine, AUC area under plasma concentration-time curve, AUC0–24 AUC from time zero to 24 h, AUC AUC from zero to infinity, AUClast AUC from time zero to time of last measurable concentration, C24 concentration at 24 h post-dose, CL/F apparent total body clearance of drug from plasma after extravascular administration, CLNR/F apparent total nonrenal body clearance of drug from plasma after extravascular administration, CLR renal clearance of drug from plasma, Cmax maximum plasma drug concentration, CV% percentage coefficient of variation, fe percentage of dose excreted unchanged in urine, PK pharmacokinetic, t½λz half-life associated with terminal slope of a semi-logarithmic concentration-time curve, tmax time to reach the maximum observed plasma concentration, Vz/F apparent volume of distribution during the terminal phase after extravascular administration

aData are summarised as geometric mean (CV%) except tmax is presented as median (min–max)